CYCN Stock Is Soaring 274% Today — What Is Fueling The Rally?

• Korsana stated that it has secured $380 million in commitments from private investors to support the merger transaction.
• The company added that its cash and cash equivalents balance at the closing of the transaction, including the funds from the private placement, is anticipated to fund the company’s operations into 2029.
• Korsana expects the financing round to close immediately prior to the proposed merger.

Cyclerion Therapeutics Inc. (CYCN) shares more than tripled in Wednesday’s opening trade, rallying by more than 274% after the company announced a deal with Korsana Biosciences Inc.

Cyclerion stated that it has entered into a definitive merger agreement for an all-stock transaction. The merged entity will operate under the name Korsana Biosciences Inc., and trade on the Nasdaq under the ticker symbol ‘KRSA’.

Retail sentiment on Stocktwits around Cyclerion Therapeutics trended in the ‘neutral’ territory at the time of writing.

Korsana Secures $380M In Commitments To Support Merger

Korsana stated that it has secured $380 million in commitments from private investors to support the merger transaction. The investment is led by Fairmount and Venrock Healthcare Capital Partners, with participation from General Atlantic, TCGX, Forbion, and Wellington Management, among others.

The company expects the financing round to close immediately prior to the proposed merger.

Korsana stated that its cash and cash equivalents balance at the closing of the transaction, including the funds from the private placement, is anticipated to fund the company’s operations into 2029, providing it with runway through key clinical milestones.

“With our seasoned team and support from leading biotechnology investors, Korsana is well-positioned to advance a pipeline of innovative, next generation therapies,” said Korsana CEO Jonathan Violin.

What Does Korsana Do?

Korsana is a Waltham, Massachusetts-based company that is engaged in the development of therapeutics to treat neurodegenerative diseases.

Its lead program is KRSA-028, a next-generation shuttle antibody targeting amyloid beta for the treatment of Alzheimer’s disease, discovered in partnership with Paragon Therapeutics.

KRSA-028 is designed to enhance amyloid plaque clearance, lower amyloid-related imaging abnormalities (ARIA) and hematologic risks, and improve convenience through low-volume subcutaneous delivery.

CYCN stock is up 357% year-to-date and 128% over the past 12 months. The Vanguard Extended Market Index Fund ETF (VXF) is up 19% over the past 12 months, while the Fidelity Nasdaq Composite Index ETF (ONEQ) is up 25%.

Also See: IPM, BCG, HUBC Among Stocks Soaring Before The Bell — Top Pre-Market Gainers Today

For updates and corrections, email newsroom[at]stocktwits[dot]com.